Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 3/20 | 0.34 |
| ▸ | BRPF1 | P55201 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21024142 | 0.81 | PIK3CD (0.39) | PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1 | |
| SCHEMBL19657574 | 0.77 | PDE3B (0.47) | PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1 | |
| SCHEMBL19657847 | 0.74 | PIK3CD (0.42) | PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1 | |
| SCHEMBL19657563 | 0.67 | PIK3CD (0.42) | PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1 | |
| SCHEMBL19287887 | 0.66 | CA2 (0.41) | ALDH1A1SMN1; SMN2HSD17B10KDM4ETP53 | |
| SCHEMBL16519582 | 0.66 | ALKBH5 (0.50) | PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1 | |
| SCHEMBL21024138 | 0.66 | ATAD2 (0.43) | PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1 | |
| SCHEMBL31248628 | 0.65 | HTT (0.37) | PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1 | |
| SCHEMBL8279315 | 0.64 | ALDH1A1 (0.57) | PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1 | |
| SCHEMBL8279209 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168070-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200399244-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-12-24 | — | — | US | disclosed |
| US-10696655-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190152949-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399244-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC3 | PIK3CD 3043/4885PIK3CA 2541/4885PIK3CB 2622/4885 |
| US-20190152949-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC11 | PIK3CD 3184/4885PIK3CA 2634/4885PIK3CB 2768/4885 |
| US-11168070-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, HDAC11 | PIK3CD 3184/4885PIK3CA 2634/4885PIK3CB 2768/4885 |
| US-10696655-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, HDAC11 | PIK3CD 3184/4885PIK3CA 2634/4885PIK3CB 2768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.